Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham–Stout disease
Kiersten Ricci(Cincinnati Children's Hospital Medical Center), Denise M. Adams(Children's Hospital of Philadelphia), Julie Blatt(Center for Cancer and Blood Disorders), Ilona J. Frieden(University of California, San Francisco), Catherine McCuaïg(Hospital for Sick Children), Stephen C. Nelson(Children’s Minnesota - St. Paul Hospital), Anna Synakiewicz(Gdańsk Medical University), Julia Glade Bender(Columbia University Irving Medical Center), Adrienne M. Hammill(Cincinnati Children's Hospital Medical Center), Paula S. Mobberley‐Schuman(Cincinnati Children's Hospital Medical Center)
Cited by 126
Related Papers
Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline
|Journal of Clinical Oncology|2004|709
Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused byRASA1 mutations
|Human Mutation|2008|429
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341
Vascular Anomalies
|Hematology/Oncology Clinics of North America|2019|122
Kaposiform lymphangiomatosis effectively treated with MEK inhibition
|EMBO Molecular Medicine|2020|104